Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 1997

View Archived Issues

SciClone awarded grant for clinical development of cystic fibrosis therapy

Quidel and Glaxo Wellcome sign agreement for diagnostic tests

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Nastech files IND for new formulation of buprenorphine

Spotlight on angiotensin II blocker/ACE inhibitor combination therapy

Patent issued for Fluorovent technology

FDA approval granted for Carbatrol

Hoechst discloses antiischemic agents

Novel neural antiapoptotic polypeptide discovered by Novartis

Aviron updates vaccine clinical program

BMS and ICAgen establish ion channel collaboration

Vanguard licenses VML-252 to Sankyo

Phase II results for ganaxolone in epilepsy and migraine anticipated by year-end

PathoGenesis receives grant for new antibiotic for CF infections

Scios/Wyeth-Ayerst commence large pivotal trials of bFGF for stroke

New immunotherapy for metastatic tumors reported

Selective iNOS inhibitor inhibits tumor growth in mice

Collagen to spin off two companies

Progress made on MMAC-1 research; Schering-Plough acquires rights to therapies

Renal effects of NO donor FK-409 in dogs

Demeter BioTechnologies awarded grant for cancer therapeutics program

VA-045 effective against TBI-induced retrograde and anterograde amnesia

ImmuCell receives grant to develop TravelGAM

DUROS leuprolide enters phase III for prostate cancer

Cubist and Merck expand antibiotic collaboration

Important NRC discovery related to stroke and epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...